Tilrekimig

Phase 3

Pfizer

Tilrekimig is one of 65 therapeutic programs targeting Asthma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

AsthmaNot yet recruiting

Atopic DermatitisRecruiting

AsthmaPhase 3

Not yet recruiting

Atopic DermatitisPhase 3

Recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Tilrekimig

Pfizer

Phase 3

1 2

Celexa

AbbVie

Preclinical

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

AstraZeneca

Preclinical

—9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Lexapro

SShirley Ryan AbilityLab

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Study completion

NCT07792941

Q2 2028

Phase 3Recruiting

Atopic Dermatitis

NCT07765888

Q2 2029

Phase 3Not yet recruiting

Atopic Dermatitis

NCT07783425

Q3 2029

Phase 3Not yet recruiting

Asthma

NCT07772921

Clinical

Trials by Indication[1]

Atopic Dermatitis2 trials

A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED PHASE 3 COMBINATION THERAPY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE OR OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07765888·375 enrolled

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE- AND PLACEBO-CONTROLLED PHASE 3 MONOTHERAPY STUDY WITH MAINTENANCE PERIOD TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Not yet recruiting· Pfizer logo

Pfizer·Phase 3·NCT07783425·1,375 enrolled

Asthma1 trial

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS WITH SEVERE ASTHMA

Not yet recruiting· Pfizer logo

Pfizer·Phase 3·NCT07772921·1,100 enrolled

Unspecified1 trial

A RANDOMISED, PHASE 1, OPEN-LABEL, SINGLE-DOSE, STUDY TO EVALUATE THE PHARMACOKINETICS AND TOLERABILITY OF TILREKIMIG IN HEALTHY PARTICIPANTS WHEN CO-MIXED WITH RHUPH20 AS A SUBCUTANEOUS INJECTION

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07792941·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Tilrekimig. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tilrekimig. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Pfizer

Tilrekimig

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Q2 2029

Q3 2029

Trials by Indication[1]

Atopic Dermatitis2 trials

Asthma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News